Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: The role of fatty acid synthase

Endocrine-Related Cancer

Volumn 17, Issue 2, 2010, Pages 539-551

  Zeng, L ^a   Biernacka, K M ^a   Holly, J M P ^a   Jarrett, C ^a   Morrison, A A ^a   Morgan, A ^a   Winters, Z E ^a   Foulstone, E J ^a   Shield, J P ^a   Perks, C M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; FATTY ACID SYNTHASE; GLUCOSE; OLEIC ACID; PALMITIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIUM CELL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; UPREGULATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CELL DEATH; CERAMIDES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; FEMALE; HUMANS; HYPERGLYCEMIA; LIPID METABOLISM; MAMMARY GLANDS, HUMAN; PALMITIC ACID; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 77953556611     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0221     Document Type: Article

References (54)

1. Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, Swanson CA, Brinton LA, Eley JW & Coates RJ 2006 General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiology, Biomarkers and Prevention 15 1871-1877.
2. Baron JA, Weiderpass E, Newcomb PA, Stampfer M, Titus-Ernstoff L, Egan KM & Greenberg ER 2001 Metabolic disorders and breast cancer risk (United States). Cancer Causes and Control 12 875-880.
3. Baserga R, Peruzzi F & Reiss K 2003 The IGF-1 receptor in cancer biology. International Journal of Cancer 107 873-877.
4. Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA, McIntosh J, McCaig C, Winters ZE & Perks CM 2006 Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 147 3484-3500.
5. Calle EE & Thun MJ 2004 Obesity and cancer. Oncogene 23 6365-6378.
6. Carroll KK 1977 Dietary factors in hormone-dependent cancers. Current Concepts in Nutrition 6 25-40.
7. Chakraborty AK, Liang K & DiGiovanna MP 2008 Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonover-expressing breast cancer. Cancer Research 68 1538-1545.
8. Claus RA, Dorer MJ, Bunck AC & Deigner HP 2009 Inhibition of sphingomyelin hydrolysis: targeting the lipid mediator ceramide as a key regulator of cellular fate. Current Medicinal Chemistry 16 1978-2000.
9. Coebergh JW, Janssen-Heijnen ML, Post PN & Razenberg PP 1999 Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. Journal of Clinical Epidemiology 52 1131-1136.
10. Costa I, Moral R, Solanas M & Escrich E 2004 High-fat corn oil diet promotes the development of high histologic grade rat DMBA-induced mammary adenocarcinomas, while high olive oil diet does not. Breast Cancer Research and Treatment 86 225-235.
11. Coughlin SS, Calle EE, Teras LR, Petrelli J & Thun MJ 2004 Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. American Journal of Epidemiology 159 1160-1167.
12. Foti M, Moukil MA, Dudognon P & Carpentier JL 2004 Insulin and IGF-1 receptor trafficking and signalling. Novartis Foundation Symposium 262 125-141.
13. Garber K 2004 Energy boost: the Warburg effect returns in a new theory of cancer. Journal of the National Cancer Institute 96 1805-1806. (Pubitemid 40081310)
14. Hardy S, El-Assaad W, Przybytkowski E, Joly E, Prentki M & Langelier Y 2003 Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. Journal of Biological Chemistry 278 31861-31870.
15. Hardy S, St-Onge GG, Joly E, Langelier Y & Prentki M 2005 Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. Journal of Biological Chemistry 280 13285-13291.
16. Hems G 1978 The contributions of diet and childbearing to breast-cancer rates. British Journal of Cancer 37 974-982. (Pubitemid 8367560)
17. Jin Q & Esteva FJ 2008 Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 485-498.
18. Key TJ, Verkasalo PK & Banks E 2001 Epidemiology of breast cancer. Lancet Oncology 2 133-140.
19. Krone CA & Ely JT 2005 Controlling hyperglycemia as an adjunct to cancer therapy. Integrated Cancer Therapy 4 25-31.
20. Kuhajda FP 2000 Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16 202-208.
21. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD & Pasternack GR 1994 Fatty acid synthesis: a potential selective target for antineoplastic therapy. PNAS 91 6379-6383.
22. Landa MC, Frago N & Tres A 1994 Diet and the risk of breast cancer in Spain. European Journal of Cancer Prevention 3 313-320. (Pubitemid 24263974)
23. Larsson SC, Mantzoros CS & Wolk A 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer 121 856-862. (Pubitemid 47106217)
24. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS & Schaffer JE 2003 Triglyceride accumulation protects against fatty acid-induced lipotoxicity. PNAS 100 3077-3082.
25. Lubin JH, Burns PE, Blot WJ, Ziegler RG, Lees AW & Fraumeni JF Jr 1981 Dietary factors and breast cancer risk. International Journal of Cancer 28 685-689. (Pubitemid 12245891)
26. Manco M, Calvani M & Mingrone G 2004 Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes, Obesity and Metabolism 6 402-413.
27. Masala G, Ambrogetti D, Assedi M, Giorgi D, Del Turco MR & Palli D 2006 Dietary and lifestyle determinants of mammographic breast density. A longitudinal study in a Mediterranean population. International Journal of Cancer 118 1782-1789.
28. Menendez JA, Lupu R & Colomer R 2004a Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/neu -overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Research and Treatment 84 183-195.
29. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R & Lupu R 2004b Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. PNAS 101 10715-10720.
30. Menendez JA, Lupu R & Colomer R 2005a Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News & Perspectives 18 375-385.
31. Menendez JA, Vellon L, Colomer R & Lupu R 2005b Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances taxol (paclitaxel)-induced cytotoxicity. International Journal of Cancer 115 19-35.
32. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA & Manson JE 2003 Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26 1752-1758.
33. Milgraum LZ, Witters LA, Pasternack GR & Kuhajda FP 1997 Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clinical Cancer Research 3 2115-2120.
34. Perks CM, Gill ZP, Newcomb PV & Holly JM 1999 Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of insulin-like growth factor I (IGF-I) in human breast cancer cell lines. British Journal of Cancer 79 701-706.
35. Pollak MN, Schernhammer ES & Hankinson SE 2004 Insulin-like growth factors and neoplasia. Nature Reviews. Cancer 4 505-518.
36. Potischman N, Coates RJ, Swanson CA, Carroll RJ, Daling JR, Brogan DR, Gammon MD, Midthune D, Curtin J & Brinton LA 2002 Increased risk of early-stage breast cancer related to consumption of sweet foods among women less than age 45 in the United States. Cancer Causes and Control 13 937-946.
37. Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W & Weiland SK 2006 Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49 945-952.
38. Repicky A, Jantova S & Milata V 2008 Signal pathways of cell proliferation and death as targets of potential chemotherapeutics. Ceskáa Slovenská Farmacie 57 4-10.
39. Richardson LC & Pollack LA 2005 Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nature Clinical Practice. Oncology 2 48-53.
40. Sabin MA, Crowne EC, Stewart CE, Hunt LP, Turner SJ, Welsh GI, Grohmann MJ, Holly JM & Shield JP 2007a Depot-specific effects of fatty acids on lipid accumulation in children's adipocytes. Biochemical and Biophysical Research Communications 361 356-361.
41. Sabin MA, Stewart CE, Crowne EC, Turner SJ, Hunt LP, Welsh GI, Grohmann MJ, Holly JM & Shield JP 2007b Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are related to ceramide production from palmitate rather than the accumulation of intramyocellular lipid. Journal of Cellular Physiology 211 244-252.
42. Shafie SM & Grantham FH 1981 Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. Journal of the National Cancer Institute 67 51-56. (Pubitemid 11087550)
43. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB & Unger RH 1998 Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. Journal of Biological Chemistry 273 32487-32490.
44. Silvera SA, Jain M, Howe GR, Miller AB & Rohan TE 2005 Dietary carbohydrates and breast cancer risk: a prospective study of the roles of overall glycemic index and glycemic load. International Journal of Cancer 114 653-658.
45. Solanas M, Hurtado A, Costa I, Moral R, Menendez JA, Colomer R & Escrich E 2002 Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet. International Journal of Oncology 21 745-753.
46. Soto-Guzman A, Robledo T, Lopez-Perez M & Salazar EP 2008 Oleic acid induces ERK1/2 activation and AP-1 DNA binding activity through a mechanism involving Src kinase and EGFR transactivation in breast cancer cells. Molecular and Cellular Endocrinology 294 81-91.
47. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF & Brooks SC 1990 Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Research 50 6075-6086. (Pubitemid 20331424)
48. Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W & Verhoeven G 2003 Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochemical and Biophysical Research Communications 302 898-903.
49. Talamini R, Franceschi S, Favero A, Negri E, Parazzini F&La Vecchia C 1997 Selected medical conditions and risk of breast cancer. British Journal of Cancer 75 1699-1703. (Pubitemid 27229065)
50. Tavani A, Giordano L, Gallus S, Talamini R, Franceschi S, Giacosa A, Montella M & La Vecchia C 2006 Consumption of sweet foods and breast cancer risk in Italy. Annals of Oncology 17 341-345.
51. Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A & Adami HO 1997 Risk of endometrial and breast cancer in patients with diabetes mellitus. International Journal of Cancer 71 360-363. (Pubitemid 27224297)
52. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K & Olsen JH 1997 Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. Journal of the National Cancer Institute 89 1360-1365.
53. Wolf I, Sadetzki S, Catane R, Karasik A & Kaufman B 2005 Diabetes mellitus and breast cancer. Lancet Oncology 6 103-111.
54. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK & Yates JW 2001 Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Journal of the American Medical Association 285 885-892. (Pubitemid 32171549)